| Library / English Dictionary |
B CELL
| Pronunciation (US): |  | (GB): | |
I. (noun)
Sense 1
Meaning:
A lymphocyte derived from bone marrow that provides humoral immunity; it recognizes free antigen molecules in solution and matures into plasma cells that secrete immunoglobulin (antibodies) that inactivate the antigens
Synonyms:
Classified under:
Hypernyms ("B cell" is a kind of...):
lymph cell; lymphocyte (an agranulocytic leukocyte that normally makes up a quarter of the white blood cell count but increases in the presence of infection)
Context examples:
Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells.
(NY-ESO-1/GLA-SE Vaccine ID-G305, NCI Thesaurus)
Two key features of the immune system are the clonal expansion of B cells and T cells in response to antigens, and the potentiation of future immune responses by long-lived memory cells.
(OX40 Signaling Pathway, NCI Thesaurus/BIOCARTA)
CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells.
(Otlertuzumab, NCI Thesaurus)
Plasma cells develop from B cells that have been activated.
(Plasma cell, NCI Dictionary)
Plasmacytes develop from B cells that have been activated.
(Plasmacyte, NCI Dictionary)
Plasma cell lymphoma, secretory B cell.
(Plasmacytoma of the Mouse Hematologic System, NCI Thesaurus/MMHCC)
Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20.
(Ofatumumab, NCI Thesaurus)
Afutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells.
(Obinutuzumab, NCI Thesaurus)
Obinutuzumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia cells.
(Obinutuzumab, NCI Dictionary)
Ocaratuzumab specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20.
(Ocaratuzumab, NCI Thesaurus)
